GLPwatch
Papers (9189)
Page 77 of 154, ranked by citation count.
- Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
- ONE MONTH WEIGHT LOSS PREDICTS THE EFFICACY OF LIRAGLUTIDE IN OBESE PATIENTS: DATA FROM A SINGLE CENTER.
- Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology.
- The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series.
- The inhibitory effects of Dulaglutide on cellular senescence against high glucose in human retinal endothelial cells.
- Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide.
- Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
- Simultaneous angiotensin receptor blockade and glucagon-like peptide-1 receptor activation ameliorate albuminuria in obese insulin-resistant rats.
- Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
- What is the evidence regarding the safety of new obesity pharmacotherapies.
- Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.
- Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
- Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
- Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.
- Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.
- Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.
- Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.
- Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
- Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.
- Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
- Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know.
- Liraglutide pharmacokinetics and exposure-response in adolescents with obesity.
- Weight loss and body composition after compounded semaglutide treatment in a real world setting.
- Protein kinase Cβ mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries.
- Control of human pancreatic beta cell kinome by glucagon-like peptide-1 receptor biased agonism.
- Protective effect of exendin-4 treatment on erectile dysfunction induced by chronic methylglyoxal administration in rats.
- Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats.
- Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
- The design of the liraglutide clinical trial programme.
- Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
- The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies.
- Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
- Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
- A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.
- α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4.
- Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
- Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies.
- Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).
- A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.
- Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line.
- Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
- The investigation of therapeutic potential of oxytocin and liraglutide on vincristine-induced neuropathy in rats.
- Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats.
- Semaglutide: a promising new glucagon-like peptide-1 receptor agonist.
- Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.
- Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis.
- Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.
- A new approach to disease-modifying drug trials in Parkinson's disease.
- Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.
- Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.
- Study protocol of the randomised placebo-controlled GLOBE trial: <i>GL</i>P-1 f<i>o</i>r <i>b</i>ridging of hyperglyca<i>e</i>mia during cardiac surgery.
- Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea.
- An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs.
- Exendin-4 attenuates lipopolysaccharides induced inflammatory response but does not protects H9c2 cells from apoptosis.
- Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.
- Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery.
- Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles.
- Age-related change of GLP-1R expression in rats can be detected by [<sup>18</sup>F]AlF-NOTA-MAL-Cys<sup>39</sup>-exendin-4.
- Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.